Journal: Oncotarget
Article Title: Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity
doi: 10.18632/oncotarget.27953
Figure Lengend Snippet: Cells were treated with 5μM erlotinib or 0.05% DMSO and stimulated with 4 nM EGF. ( A ) Differentially expressed miRNAs between erlotinib sensitive and insensitive primary human keratinocyte cell samples (fold change ≥ 1.5 or fold change ≤ 0.66, p -value ≤ 0.05). ( B ) Differentially expressed miRNAs between erlotinib sensitive and insensitive human dermal fibroblast cell samples (fold change ≥ 1.5 or fold change ≤ 0.66, p -value < 0.01) Abbreviation: EGF: epidermal growth factor.
Article Snippet: Before miRNA profiling keratinocytes were incubated with 5μM erlotinib (SantaCruz Biotechnology, Dallas, TX, USA) or 0.05% DMSO for two hours and then stimulated with 4 nM EGF (PeproTech, Rocky Hill, NJ, USA) for 5 min. Fibroblasts were incubated with 5 μM erlotinib or 0.05% DMSO for 24 hours and then stimulated with 4nM EGF for 5 min.
Techniques: